

Funded vaccines for special groups from 1st July 2017

Please refer to the individual vaccines on the following pages for detailed eligibility criteria and the *Immunisation Handbook 2017 2nd Edition* for vaccine administration schedules

Asplenia – Functional or Pre- or Post-Splenectomy Immunisation Programme <ul style="list-style-type: none"> • Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines 	Influenza Immunisation Programme <ul style="list-style-type: none"> » Pregnancy, » Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness, » Individuals aged 6 months to under 65 years with an eligible medical condition, » Individuals aged 65 years or older, » Individuals aged under 18 years living in specified earthquake or flood affected areas in Bay of Plenty, Nelson Marlborough or Canterbury District Health Boards.
Chemotherapy – following <ul style="list-style-type: none"> • Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines Also consider immunosuppression for longer than 28 days <ul style="list-style-type: none"> • Hepatitis B and meningococcal vaccines 	<ul style="list-style-type: none"> • Influenza vaccine
Cochlear implant <ul style="list-style-type: none"> • Hib, influenza, and pneumococcal vaccines 	Kidney disease <ul style="list-style-type: none"> • Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines
Error of metabolism at risk of major metabolic decompensation <ul style="list-style-type: none"> • Influenza and varicella vaccines 	Liver disease <ul style="list-style-type: none"> • Hepatitis A and varicella vaccines
Haematopoietic stem cell transplantation (HSCT) – following <ul style="list-style-type: none"> • Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines Also consider immunosuppression for longer than 28 days <ul style="list-style-type: none"> • Hepatitis B vaccine 	Meningococcal disease case – contact with <ul style="list-style-type: none"> • Meningococcal vaccine
Hepatitis A case – contact with <ul style="list-style-type: none"> • Hepatitis A vaccine 	Needle stick injury – following <ul style="list-style-type: none"> • Hepatitis B vaccine
Hepatitis B case – contact with <ul style="list-style-type: none"> • Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth Household and sexual contacts of known acute hepatitis B cases or carriers <ul style="list-style-type: none"> • Hepatitis B vaccine 	Non-consensual sexual intercourse – following <ul style="list-style-type: none"> • Hepatitis B vaccine
Hepatitis C positive individual <ul style="list-style-type: none"> • Hepatitis B vaccine 	Pneumococcal disease – increased risk <ul style="list-style-type: none"> • Additional pneumococcal vaccines
HIV positive individual <ul style="list-style-type: none"> • Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines 	Pregnancy <ul style="list-style-type: none"> • Influenza and Tdap vaccines in every pregnancy
Immune deficiency/immunosuppression <ul style="list-style-type: none"> • Hepatitis B, Hib, influenza, meningococcal, pneumococcal, and varicella vaccines 	Rubella – women of childbearing age who are not immune to rubella <ul style="list-style-type: none"> • MMR vaccine
Individuals with an immune deficiency <ul style="list-style-type: none"> • Influenza, meningococcal, and pneumococcal vaccines 	Solid organ transplantation <ul style="list-style-type: none"> • Hepatitis A, hepatitis B, Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines
Household contacts of children or adults who will be/are immunosuppressed <ul style="list-style-type: none"> • Varicella vaccine 	Prior to solid organ transplantation <ul style="list-style-type: none"> • Hepatitis A, hepatitis B, Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines
Prior to elective immunosuppression for longer than 28 days <ul style="list-style-type: none"> • Varicella vaccine 	Following solid organ transplantation <ul style="list-style-type: none"> • Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines
Following immunosuppression for longer than 28 days <ul style="list-style-type: none"> • Hepatitis B, Hib, influenza, meningococcal, and Tdap vaccines 	Tuberculosis – infants and children aged under 5 years at risk of tuberculosis (TB) exposure <ul style="list-style-type: none"> • BCG vaccine

Vaccine key – BCG: tuberculosis; **Hib:** *Haemophilus influenzae* type b; **HPV:** human papillomavirus; **MMR:** measles, mumps, rubella; **Tdap:** tetanus, diphtheria, acellular pertussis; **varicella:** chickenpox.

Funded vaccines for special groups from 1st July 2017

Vaccine	Individuals eligible for funded vaccine
BCG vaccine (Bacillus Calmette-Guérin) (Chapter 20 [#]) UPDATED	<p>Infants and children aged under 5 years</p> <ul style="list-style-type: none"> • Living in a house or family with a person with current or past history of tuberculosis (TB), or • Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB at 40/100,000 or greater for 6 months or longer, or • During their first 5 years will be living 3 months or longer in a country with a rate of TB 40/100,000 or greater
<i>Haemophilus influenzae</i> type b (Hib) vaccine (Chapter 6 [#])	<ul style="list-style-type: none"> • An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen
Hepatitis A vaccine (Chapter 7 [#])	<ul style="list-style-type: none"> • One dose for close contacts of a hepatitis A case • Two doses for transplant patients; or children with chronic liver disease
Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (Chapter 8 [#])	<ul style="list-style-type: none"> • Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*; non-consensual sexual intercourse; or needle stick injury (5mcg/0.5mL or 10mcg/1.0mL as appropriate) • Children under the age of 18 years who are considered not to have achieved a positive serology and require additional vaccination (5mcg/0.5mL or 10mcg/1.0mL as appropriate) • Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg/1.0mL)
Human papillomavirus (HPV) vaccine (Chapter 9 [#])	<ul style="list-style-type: none"> • Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive • A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy
Influenza vaccine (Chapter 10 [#] and the Influenza Kit)	<ul style="list-style-type: none"> • Pregnant women in every pregnancy during vaccination season • Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness • Individuals aged 65 years and older • Individuals aged 6 months to under 65 years with certain medical conditions, as per the Influenza Kit, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation • Individuals aged under 18 years living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board); or who have been displaced from their homes in Edgecumbe and the surrounding region (Bay of plenty District Health Board)
Meningococcal conjugate vaccines (under 2 years MenCCV and 2 years or older MCV4-D) (Chapter 12 [#])	<ul style="list-style-type: none"> • One dose for close contacts of a meningococcal disease case • Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days* • Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive
Tetanus, diphtheria and pertussis (Tdap) vaccine (Chapter 14 [#])	<ul style="list-style-type: none"> • One dose for pregnant women, between gestational weeks 28 and 38 of every pregnancy • Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen

[#] Refer to recommended chapter in the Immunisation Handbook 2017 2nd Edition.

* For example chemotherapy regimens to treat cancer, conditioning regimes prior to haematopoietic stem cell transplantation, and treatment of immune mediated inflammatory disease.

Funded vaccines for special groups from 1st July 2017

Vaccine	Individuals eligible for funded vaccine
Pneumococcal conjugate (PCV13) vaccine (Chapter 15 [#]) UPDATED	<p>Children aged under 5 years – up to four age-appropriate doses Children aged 18 months to under 18 years who have previously received four doses of PCV10 – one dose Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</p> <p>Children aged 5 years or older, and adults – up to four age-appropriate doses Post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</p>
Pneumococcal polysaccharide (23PPV) vaccine (Chapter 15 [#]) UPDATED	<p>Children aged 2 years to under 18 years – up to two doses (as appropriate) Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure</p> <p>Adults aged 18 years or older – up to three doses (as appropriate) Post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</p>
Varicella vaccine (Chapter 21 [#])	<p>Two doses for non-immune individuals:</p> <ul style="list-style-type: none"> • Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist • Prior to elective immunosuppressive therapy that will be longer than 28 days[‡] • With chronic liver disease who may in future be candidates for transplantation • With deteriorating renal function before transplantation • Pre-solid organ transplantation • Post-haematopoietic stem cell transplantation, on the advice of their specialist • Post-chemotherapy, on the advice of their specialist • Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis <p>Two doses for individuals with no clinical history of varicella infection or immunisation:</p> <ul style="list-style-type: none"> • With an inborn error of metabolism at risk of major metabolic decompensation • Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation • Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation

[#] Refer to recommended chapter in the Immunisation Handbook 2017 2nd Edition.

[‡] For example treatment of immune mediated inflammatory disease.